NASDAQ$INGN
Inogen Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Inogen's revenue decreased due to the impacts of the COVID-19 pandemic, but rental revenue increased.
Inogen reported a decrease in total revenue for Q4 2020, primarily due to the COVID-19 pandemic's impact on direct-to-consumer and international business-to-business sales channels. However, the company saw a rebound in domestic business-to-business sales and strong growth in rental revenue.
- Total revenue decreased by 6.3% to $74.0 million compared to the same period in 2019.
- Domestic business-to-business sales increased by 17.9% to $24.2 million compared to the same period in 2019.
- Rental revenue increased by 71.7% to $9.4 million compared to the same period in 2019.
- Net loss was $5.1 million.
Headline financials
Revenue & EPS history
Inogen · Revenue · Quarterly
$74M
Forward guidance
Due to unprecedented market uncertainties, the Company is unable to provide guidance for the full year 2021.
Tailwinds
- Demand has increased so far in the first quarter of 2021 from the Company’s domestic HME partners in part, due to increased demand for POCs as hospital systems and stationary oxygen concentrator supply have been strained to keep up with the rapid increase in COVID-19 cases.
- The Company expects its domestic business-to-business sales to increase in the first quarter of 2021 versus the comparative period in the prior year.
- The Company expects its rental revenue to grow in the first quarter of 2021 compared to the same period in the prior year due to increased patients on service, higher billable patients as a percent of total patients on service, and higher average reimbursement rates.
- The Company believes it is prudent to make investments to support its strategy to focus on rentals at the onset-of-care.
- The Company plans to invest to expand its physician sales force and to build the infrastructure to enable it to offer physicians the necessary solutions to better serve their patients’ needs.
Headwinds
- Given the uncertain scope and duration of the COVID-19 pandemic, the Company is unable to estimate the impact on its financial results, including revenue, net income or loss, and Adjusted EBITDA estimates for such period.
- The Company also expects its international business-to-business and direct-to-consumer sales channels in the first quarter of 2021 to decrease compared to the same period in the prior year as a result of the continued COVID-19 impact on these channels.
- The Company expects the COVID-19 pandemic and any potential for further, prolonged lockdowns would have a negative impact on its sales revenue.
- The Company expects increased operating expense for the year in 2021.
- The Company incurred minimal expenses related to bonus and performance-based stock compensation in 2020, and it expects such costs to increase in 2021 along with certain expenses related to the recent CEO transition.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.7%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-2.0%
Avg return
30 days after
49%
26 / 53 earnings
Positive
+35.5%
Q2 2024
Best reaction
-32.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | -5.3% | -11.0% | |
| Q4 2025 | +4.3% | +5.8% | +6.0% | |
| Q3 2025 | -0.6% | +0.9% | -1.3% | |
| Q1 2025 | -11.5% | -14.4% | -8.1% | |
| Q4 2024 | -14.8% | -14.6% | -28.6% | |
| Q3 2024 | +15.9% | +9.1% | -0.7% | |
| Q2 2024 | +35.5% | +50.6% | +43.0% | |
| Q1 2024 | +14.6% | +17.7% | +17.7% | |
| Q4 2023 | -32.2% | -24.3% | -13.0% | |
| Q3 2023 | -1.3% | -8.1% | +10.0% | |
| Q2 2023 | -14.6% | -18.7% | -20.8% | |
| Q1 2023 | -6.1% | -19.3% | -21.9% | |
| Q4 2022 | -31.4% | -32.4% | -46.4% | |
| Q3 2022 | -12.5% | -10.0% | -0.8% | |
| Q2 2022 | -6.9% | -7.3% | -6.3% | |
| Q1 2022 | -2.2% | -7.8% | +2.0% | |
| Q4 2021 | +12.6% | +25.3% | +13.5% | |
| Q3 2021 | -6.0% | -7.3% | -21.6% | |
| Q2 2021 | -22.8% | -16.8% | -22.1% | |
| Q1 2021 | -3.5% | -2.4% | -12.8% | |
| Q4 2020 | +4.6% | +5.4% | -4.2% | |
| Q3 2020 | -7.1% | +9.8% | +33.0% | |
| Q2 2020 | +16.4% | +17.0% | -6.5% | |
| Q1 2020 | -21.4% | -20.1% | -24.2% | |
| Q4 2019 | +10.2% | +5.4% | +26.4% | |
| Q3 2019 | +17.3% | +19.7% | +24.4% | |
| Q2 2019 | -15.4% | -18.5% | -20.9% | |
| Q1 2019 | -28.8% | -22.2% | -31.8% | |
| Q4 2018 | -26.4% | -25.9% | -35.1% | |
| Q3 2018 | -18.8% | -22.6% | -24.8% | |
| Q2 2018 | +7.7% | +6.3% | +21.3% | |
| Q1 2018 | +21.0% | +18.7% | +26.7% | |
| Q4 2017 | -9.3% | -8.4% | -7.8% | |
| Q3 2017 | +16.1% | +12.9% | +15.0% | |
| Q2 2017 | -5.6% | -3.9% | +0.3% | |
| Q1 2017 | +0.2% | -2.6% | +11.9% | |
| Q4 2016 | +6.8% | +6.0% | +11.4% | |
| Q3 2016 | +13.0% | +15.8% | +22.3% | |
| Q2 2016 | +0.9% | +9.3% | +8.9% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +20.6% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +4.9% | — | — | |
| Q4 2014 | +1.8% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q3 2013 | -1.7% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +3.6% | — | — | |
| Q2 2013 | +3.6% | — | — | |
| Q1 2013 | +12.7% | — | — | |
| Q1 2014 | +12.7% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro